CTXRW - (Citius Pharmaceuticals Inc.)

 CTXRWのチャート


 CTXRWの企業情報

symbol CTXRW
会社名
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種   
概要 事業概要 --     
本社所在地 --
代表者氏名
代表者役職名
電話番号
設立年月日 --
市場名 --
ipoyear ―年
従業員数 -
url
nasdaq_url https://www.nasdaq.com/symbol/ctxrw
adr_tso
EBITDA EBITDA ー
終値(lastsale) 0.2432
時価総額(marketcap) 0
時価総額 時価総額 ―
売上高 売上高 --
企業価値(EV) 企業価値(EV) ー
当期純利益 当期純利益 --
決算概要 決算概要 --

 CTXRWのテクニカル分析


 CTXRWのニュース

   Citius Pharmaceuticals provides late-stage Mino-Lok trial timeline update  2021/06/08 13:10:03 Seeking Alpha
   Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial  2021/06/08 00:00:00 BioSpace
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), today announced that the next planned interim analysis in its Phase 3 trial of Mino-Lok.
   Citius Pharmaceuticals set to join Russell 2000 Index  2021/06/07 14:20:07 Seeking Alpha
   Citius Pharmaceuticals to be Added to Russell 2000® Index  2021/06/07 00:00:00 BioSpace
Citius Pharmaceuticals, Inc. today announced that it is set to be added to the Russell 2000® Index at the conclusion of the Russell US Indexes annual reconstitution, effective at the opening of the U.S. equity markets on June 28, 2021.
   Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting  2021/05/25 18:52:00 Business Insider Markets
CRANFORD, N.J., May 25, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on
   EXCLUSIVE: Citius Pharmaceuticals CEO Myron Holubiak Talks Company Advantages  2021/05/13 21:09:36 Benzinga
Myron Holubiak, president and CEO of Citius Pharmaceuticals Inc (NASDAQ: CTXR ), appeared Thursday at Benzinga's Global Small Cap Conference for an exclusive interview. The name Citius Pharmaceuticals comes from the Olympic motto "Citius, Altius, Fortius," which is Latin for "Faster, Higher, Stronger," Holubiak told Benzinga. The Citius CEO told Benzinga that he and executive chairman Leonard Mazur have collectively invested $26 million in the company. Mino-Lok: Citius' lead asset Mino-Lok is an antibiotic lock solution drug that is used in the treatment of catheter-related bloodstream infections. Mino-Lok is in late stage three clinical studies, Holubiak said. When a catheter gets infected, the current solution is the costly … Full story available on Benzinga.com
   Citius Thrives in 2021 with Critical Care Solutions for ARDS Associated with COVID-19  2021/04/19 12:53:14 Benzinga
The following article is sponsored by Citius Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Companies like Pfizer, Inc. ( NYSE: PFE ) , Syndax Pharmaceuticals ( NASDAQ: SNDX ), Merck & Co. ( NYSE: MRK ), and Amgen, Inc. (NASDAQ: AMGN ), among others, understand the importance of creating new, effective pharmaceutical critical care products for unmet needs. For example, long-term patients with central venous catheters (CVCs) for dialysis or cancer treatments are still at risk for complications related to bloodstream infections that might be fatal. This creates a new set of needs in order to have successful outcomes for these patients. Finding ways to avoid these complications can be lifesavers. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR ), a specialty pharmaceutical company dedicated to developing and commercializing novel critical care drug products, is addressing several of these unmet medical needs with cost-saving and cost-effective solutions with low-risk development pathways.
   Thinking about buying stock in Nio, Norwegian Cruise Line, Immunovant, Devon Energy, or Citius Pharmaceuticals?  2021/03/08 15:55:00 PR Newswire
NEW YORK, March 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, NCLH, IMVT, DVN, and CTXR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts  2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
   Thinking about buying stock in Sundial Growers, AMC Entertainment, Northern Dynasty Minerals, Citius Pharmaceuticals, or Hepion Pharmaceuticals?  2021/02/18 15:55:00 PR Newswire
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, AMC, NAK, CTXR, and HEPA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Citius Thrives in 2021 with Critical Care Solutions for ARDS Associated with COVID-19  2021/04/19 12:53:14 Benzinga
The following article is sponsored by Citius Pharmaceuticals, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Companies like Pfizer, Inc. ( NYSE: PFE ) , Syndax Pharmaceuticals ( NASDAQ: SNDX ), Merck & Co. ( NYSE: MRK ), and Amgen, Inc. (NASDAQ: AMGN ), among others, understand the importance of creating new, effective pharmaceutical critical care products for unmet needs. For example, long-term patients with central venous catheters (CVCs) for dialysis or cancer treatments are still at risk for complications related to bloodstream infections that might be fatal. This creates a new set of needs in order to have successful outcomes for these patients. Finding ways to avoid these complications can be lifesavers. Citius Pharmaceuticals, Inc. (NASDAQ: CTXR ), a specialty pharmaceutical company dedicated to developing and commercializing novel critical care drug products, is addressing several of these unmet medical needs with cost-saving and cost-effective solutions with low-risk development pathways.
   Thinking about buying stock in Nio, Norwegian Cruise Line, Immunovant, Devon Energy, or Citius Pharmaceuticals?  2021/03/08 15:55:00 PR Newswire
NEW YORK, March 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, NCLH, IMVT, DVN, and CTXR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts  2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
   Thinking about buying stock in Sundial Growers, AMC Entertainment, Northern Dynasty Minerals, Citius Pharmaceuticals, or Hepion Pharmaceuticals?  2021/02/18 15:55:00 PR Newswire
NEW YORK, Feb. 18, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SNDL, AMC, NAK, CTXR, and HEPA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Citius Pharmaceuticals Is Addressing Several Unmet Needs In The Medical Field  2021/02/04 15:16:13 Benzinga
Citius Pharmaceuticals, Inc. was one of the sponsors for the Benzinga Global Small-Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Despite current medical advances, there are still many medical conditions with unmet needs. For example, long-term patients with Central Venous Catheters (CVCs) for dialysis or cancer treatment are still at risk for complications related to bloodstream infections that might be fatal. Complications associated with CVC placement can present a 12%-25% morbidity and mortality, resulting in burdening hospitals and healthcare institutions with costs, hospital days, and patient quality of life. Thus, management and prevention should be the ultimate goal for positive treatment outcomes. A company that understands the importance of unmet needs is Citius Pharmaceuticals, Inc. (NASDAQ: CTXR ).

 関連キーワード  (― 米国株 CTXRW Citius Pharmaceuticals Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)